---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-030839"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2021-12-08T23:59:59+00:00"
generated_at: "2026-06-28T02:50:05.703591+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Biotricity CEO letter cites record Q2 revenue of $1.81M (+143% YoY), sets 2022 goals

## Summary
- Record quarterly revenue of $1.81M for Q2 FY2022 ended Sep 30, 2021, up 143% YoY, tenth consecutive triple-digit growth quarter.
- Recent uplisting to Nasdaq to attract larger investor pool and increase liquidity.
- Introduced Biokit, a 3-device personal medical kit for integration into Biotricity ecosystem.
- Product roadmap includes Bioflux, Biotres, Biocare Telemed, and Bioheart.
- 2022 goals: launch new cardiac monitoring solutions and software services to become turnkey cardiac health provider.

## SEC filing metadata
- accession: 0001493152-21-030839
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2021-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315221030839/0001493152-21-030839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315221030839/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-030839
- JSON: https://secwatch.observer/filing/0001493152-21-030839.json
- Plain text: https://secwatch.observer/filing/0001493152-21-030839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.